

## Cervical / Endometrial Cancer Treatment

---

Reference Number: F4900  
Date of Response: 05/10/2022

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

### **Royal Devon's Eastern FOI Office Response**

Q1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for the following conditions? **Yes**

- Cervical cancer
- Endometrial cancer

In case you do not provide SACT treatments for either of the above conditions, which other trust do you refer patients to for these treatments?

Q2. How many patients were treated for cervical cancer in the past 6 months with the following treatments:

- Paclitaxel in combination with Platinum and/or Bevacizumab \* <5
- Pembrolizumab in combination with Platinum and/or Bevacizumab \* <5
- Platinum standalone or in combination with Bevacizumab \* <5
- Topotecan in combination with Platinum and/or Bevacizumab **0**
- Any other SACT **0**

Q3. How many patients were treated for endometrial cancer in the past 6 months with the following treatments:

- Dostarlimab **0**
- Hormone therapy (Progesterone or Letrozole) **0**
- Pembrolizumab in combination with Lenvatinib **0**
- Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) **6**
- Any other SACT \* <5

Q4. How many endometrial cancer patients received the following therapies as 1<sup>st</sup> Line treatment in the past 6 months:

- Hormone therapy (Progesterone or Letrozole)\* <5
- Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) \* <5
- Any other SACT\* <5

Q5. Does your trust participate in any clinical trials for the treatment of cervical cancer? If so, can you please provide the name of each trial and the number of patients taking part.

**Interlace 54 patients (across 2 hospital sites)**

**Mk3475-A18 / ENGOT-cx11 <5**

Q6. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.

**AtTEnd - Atezolizumab in Endometrial cancer <5 patients**

**\*≤5. Were indicated.**

**In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles**